1Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes, 2000,49 : 633-639.
3Willson TM, Brown PJ, Sternbach DD, et al. The PPARs:from orphan receptors to drug discovery. J Med Chem,2000,43:527-550.
4Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest,2000,106:467-472.
5Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest, 1997, 100:2900-2906.
6Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev,2000,14:121-141.
7Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes, 2000,49:539-547.
8Ribon V, Johnson JH, Camp HS, et al. Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sic USA, 1998,95: 14751-14756.
9Gillies PS, Dunn CJ. Pioglitazone. Drugs,2000,60: 333-343.
10Burris TP, Pelton PD, Zhou L, et al. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptorgamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol Endocrinol, 1999,13 : 410-417.
二级参考文献6
1Porter L E,Freed M I,Jones N P,et al.Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes[].Diabetes.2000
2Rubin C,Egan J,Schneider R.Combination therapy with pioglitazone and insulin in patients with type 2 diabetes[].Diabetes.1999
3Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of Pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus[].Diabetes.2000
4Spiegelman BM.PPARγadipogenic regulator and thiozolidinedione receptor[].Diabetes.1998
8Groop L C. Huulin resistance:the fundamental trigger of type2 diabetes[J]. Diabetes Obes Metab, 1999, 1 (Suppll) :S1-S7.
9Gegick C G,Altheimer M D. Comparion of effects of thiazolidinediones on cardiovascular risk factors:observations from a clinical practice[J]. Endoct Praet, 2001,7(3) : 162.
10[3]American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care,2001,24(Suppl 1 ): 33-43.
